Mutagenic Evaluation of Compound FDA 73-53 Malt Extract 6/15/75

F19

MUTAGENIC EVALUATION OF COMPOUND FDA 73-53 977051174 MALT EXTRACT

SUBMITTED TO

FOOD & DRUG ADMINISTRATION
DEPARTMENT OF HEALTH, EDUCATION AND WELFARE
ROCKVILLE, MARYLAND

SUBMITTED BY

LITTON BIONETICS, INC. 5516 NICHOLSON LANE KENSINGTON, MARYLAND

JUNE 15, 1975



TABLE OF CONTENTS

EVALUATION	N SUMMARYPa	age No.						
I.	OBJECTIVE							
II.	MATERIALS	2						
·	A. Test Compound B. Indicator Microorganisms C. Reaction Mixture D. Tissue Homogenates and Supernatants E. Positive Control Compounds	2 2 3						
III.	METHODS	3						
	A. Toxicity B. Plate Tests C. Suspension Tests D. Preparation of Tissue Homogenates and 9,000 x g Cell	4 4 I						
	Fractions E. Data Recording and Reporting	5 5						
IV.	RESULTS SECTION	6						
	A. Solubility Properties of the Test Compound B. Toxicity and Dosage Determinations for the Test Compound							
٧.	SUMMARY OF TEST RESULTS	. 7						
VI.	INTERPRETATION OF RESULTS AND CONCLUSIONS	.14						
	A. Salmonella typhimurium B. Saccharomyces cerevisiae Conclusions	.14						
APPFNDIX-1	TARIII ATION OF DATA	Δ_1						



EVALUATION SUMMARY

Compound FDA 73-53, Malt Extract, did not exhibit genetic activity in any of the \underline{in} \underline{vitro} microbial assays employed in this evaluation.



DATE:

June 15, 1975

SPONSOR:

Food and Drug Administration, Contract Number 223-74-2104

SUBJECT:

Evaluation of Test Compound 977051174, Malt Extract FDA 73-53

I. OBJECTIVE

The objective of this study was to evaluate the test compound for genetic activity in microbial assays with and without the addition of mammalian metabolic activation preparations.

II. MATERIALS

A. <u>Test Compound</u>

1. Date Received: August, 1974

2. Description: viscous brown syrup

B. <u>Indicator Microorganisms</u>

The following strains of indicator microorganisms were used in the evaluation:

Yeast Strain:

Saccharomyces cerevisiae, strain D4

Bacteria Strains:

Salmonella typhimurium, strains:

TA-1535 TA-1537

TA-1538

C. Reaction Mixture

The following reaction mixture was employed in the activation tests:

Component	Final Concentration/ml
1. TPN (sodium salt)	6 μ M
2. Isocitric acid	49 ⁻ սM
3. Tris buffer, pH 7.4	28 _u M
4. MgCl ₂	1.7 _u M
5. Tissue homogenate fraction	72 mg



D. <u>Tissue Homogenates and Supernatants</u>

The tissue homogenates and 9,000 x <u>g</u> supernatants were prepared from tissues of the following mammalian species: Mouse-ICR random bred adult males; rat-Sprague-Dawley adult males; and primate-<u>Macaca</u> mulatta adult males.

E. <u>Positive Control Compounds</u>

Table 1 lists chemicals for positive controls in the direct and activation assays.

TABLE 1 POSITIVE CONTROLS USED IN DIRECT AND ACTIVATION ASSAYS

<u>Assay</u>	<u>Chemical^a</u>	Solvent	Probable Mutagenic Specificity
Nonactivation	Ethyl methanesulfonate 2-Nitrofluorene Quinacrine mustard	Water or saline Dimethylsulfoxide ^c Water or saline	BPS ^b FS ^b
Activation	Dimethylnitrosamine 2-Acetylaminofluorene	Water or saline Dimethylsulfoxide ^C	BPS ^b FS

Concentrations given in the Results Section
 BPS = base-pair substitution; FS = frameshift

Previously shown to be non-mutagenic

III. METHODS

A. Toxicity

The solubility, toxicity and doses for all chemicals were determined prior to screening.

Each chemical was tested for survival against the specific indicator strains over a range of doses to determine the 50% survival dose. Bacteria were tested in phosphate buffer, pH 7.4, for one hour at 37°C on a shaker. Yeasts were tested in phosphate buffer, pH 7.4, for four hours at 30°C on a shaker. The 50% survival curve and the 1/4 and 1/2 50% doses calculated.

If no toxicity was obtained for a chemical with a given strain, then a maximum dose of 5% (w/v) was used against the strain.

Unless otherwise specified, the doses calculated for the tests in buffer were applied to the activation tests. The solubility of the test chemical under treatment conditions is stated in the Results Section.



B. Plate Tests

In the nonactivation procedure, approximately 10° cells of a log phase culture of the bacterial indicator strains were spread over the surface of a minimal plate, and a measured amount of the test chemical was placed in the center of the test plate. In activation tests, the test chemical was added to the cells, and an aliquot of the mixture was spread on the surface of the test plate. The reaction mixture (0.1 ml) plus tissue extract was then spotted on the surface of the plate. Positive and solvent controls were included. All plates were incubated at 37°C for four days and then scored. Each compound (Test, Positive Control and Solvent Control) was done in duplicate. Concentrations of the positive control compounds are listed in the Results Section.

C. <u>Suspension Tests</u>

Nonactivation

Log-phase bacteria and stationary-phase yeast cultures of the indicator organisms were grown in complete broth, washed and resuspended in 0.9% saline to densities of 1 x 10^9 cells/ml and 5 x 10^7 cells/ml, respectively. This constituted the working stock for tests of a group of test chemicals and their respective controls. Tests were conducted in plastic tissue culture plates. Cells plus appropriate volume(s) of the test chemical were added to the wells to give a final volume of 1.5 ml. The solvent replaced the test chemical in the negative controls. Treatment was at 30°C for four hours for yeast tests and at 37°C for one hour for bacterial tests. All flasks were shaken during treatment. Following treatment, the plates were set on ice. Aliquots of cells were removed, diluted in sterile saline (4°C) and plated on the appropriate complete media. Undiluted samples from flasks containing the bacteria were plated on minimal selective medium in reversion experiments. from a 10⁻¹ dilution of treated cells were plated on the selected media for enumeration of gene conversion with strain D4. Bacterial plates were scored after incubation for 48 hours at 37°C. The yeast plates were incubated at 30°C for 3-5 days before scoring.

2. Activation

Bacteria and yeast cells were grown and prepared as described in the nonactivation tests. Measured amounts of the test and control chemicals plus 0.25 ml of the stock-cell suspension were added to wells of the Linbro plate containing the appropriate tissue fraction and reaction mixture. All flasks (bacteria and yeast) were incubated at 37°C in an oxygen atmosphere with shaking. The treatment times as well as the dilutions, plating procedures and scoring of the plates were the same as described for nonactivation tests.



D. Preparation of Tissue Homogenates and 9,000 x g Cell Fractions

Male animals (sufficient to provide the necessary quantities of tissues) were killed by cranial blow, decapitated and bled. Organs were immediately dissected from the animal using aseptic techniques and placed in ice-cold 0.25 M sucrose buffered with Tris at pH of 7.4. Upon collection of the desired quantity of organs, they were washed twice with fresh buffered sucrose and completely homogenized with a motor-driven homogenizing unit at 4° C. The whole organ homogenate obtained from this step was divided into two samples. One sample was frozen at -80° C and the other was centrifuged for 20 minutes at 9,000 x g in a refrigerated centrifuge. The supernatant from the centrifuged sample was retained and frozen at -80° C. These two frozen samples were used for the activation studies.

E. <u>Data Recording and Reporting</u>

Following the specified incubation periods all population plates were scored by an automatic colony counter and the results from each plate of a set were recorded, in ink, on data processing forms. All minimal or other types of selective media plates were hand scored and the results recorded along with the respective population data. Other relevant experimental data were recorded on experimental definition forms. For bacteria strains the number of colonies recorded from either the population or selective plates represents that number in 1 ml of test suspension plated. The numbers recorded for the yeast strain D4 represent the number in 0.5 ml of test suspension plated. The data were then processed and printed from a computer program.



- IV. RESULTS SECTION
- A. Solubility Properties of the Test Compound
- 1. Name or code designation of the test compound: 977051174 Malt Extract
- 2. Test solvent: Saline
- 3. Solubility of the test compound under treatment conditions: Soluble under treatment conditions
- 4. Additional comments: Viscous brown syrup
- B. Toxicity and Dosage Determinations for the Test Compound
- 1. Test date for toxicity determination: April 11, 1975
- 2. The 50% survival level was determined for bacteria and yeast indicator organisms by conducting survival curves with the test compound at the following concentrations:

Percent Concentration (w/v or v/v)

10.0 1.0 0.1 0.01 0.001

3. Concentrations of the test compound used in the mutagenicity tests:

	Percent Conc	entration
Dose	Bacteria	Yeast
1/4 50% Survival	2.5	2.5
1/2 50% Survival	5.0	5.0
50% Survival	10.0	10.0
Plate Tests	2.5	



V. SUMMARY OF TEST RESULTS

Plate Tests

A. Name or code designation of the test compound: 977051174

B. Test date: April 21, 1975

C. Concentration of the test compound: 2.5%

					REVER	TANTS/P	LATE	
Test	<u>Species</u>	<u>Tissue</u>	TA-	<u>-1535</u>		<u>-1537</u>		<u>-1538</u>
1. Non-activation			<u>_</u>	2	1	2	1	2
Solvent Control	60 00 00		3	4	22	33	7	11
Positive Control ^a	60 00 00		>10 ⁵	>10 ⁵	138	133	146	138
Test Compound	50 00 00		11	9	23	27	23	22
2. Activation								
Negative Control Solvent Control Reaction Mixture	·		6 10	4 12	27 36	23 43	7 16	14 18
Control			9	7	36	39	19	23
Positive Control ^b	Mouse	Liver	>10 ³	>10 ³	96	93	333	317
Positive Control		Lung	9	7	33	33	21	26
Positive Control		Testes	7	2	37	32	18	11
Positive Control	Rat	Liver	>10 ³	>10 ³	84	80	314	317
Positive Control		Lung	11	6	32	35	15	18
Positive Control		Testes	6	5	24	43	20	9
Positive Control	Monkey	Liver	>10 ³	>10 ³	97	93	111	155
Positive Control		Lung	8	5	32	38	13	15
Positive Control		Testes	8	2	28	33	12	8
Test Compound	Mouse	Liver	4	7	39	40	16	14
Test Compound		Lung	5	2	24	26	12	8
Test Compound		Testes	6	7	28	32	15	23
Test Compound	Rat	Liver	6	9	36	39	16	14
Test Compound		Lung	5	2	18	26	14	13
Test Compound		Testes	4	8	29	19	17	21
Test Compound	Monkey	Liver	4	11	34	39	16	14
Test Compound		Lung	3	2	28	28	15	18
Test Compound		Testes	5	4	29	22	13	18
TA-1537 QM 20	μl/plate μg/plate μg/plate	TA-	-1535 -1537 -1538	DMNA AAF AAF	100	μ M/plat μ g/plat μ g/plat	е.	



DATA TABLE TERMS AND ABBREVIATIONS

Client designa	DEFINITION OR EXPLANATION				
Client designa this column.	ted compound number appears in				
	Client designated compound number appears in this column.				
NAN NAP NA1 NA2, etc.	<pre>= Nonactivation: Solvent Control = Nonactivation: Positive Control = Nonactivation: Test Compound Dose = Reflects the other dose level(s)</pre>				
A+C A-C ACP ACT A+T	<pre>= Negative Chemical Control = Activation: Solvent Control = Activation: Positive Control = Activation: Test Compound = Activation: Tissue Control</pre>				
LI LU KI TE 1,2, etc.	 Liver Tissue Activation Fraction Lung Tissue Activation Fraction Kidney Tissue Activation Fraction Testes Tissue Activation Fraction Dose Levels 				
All test compound dose levels are expressed as a whole number followed by an exponent (negative) identified by the appropriate units.					
Example: 0025	-2PCT = 0.25 percent concentration				
Total number of viable cells in the plating sample raised to some exponent printed directly below the abbreviation (i.e., $EP + 6 = x \cdot 10^6$).					
Total number of mutants or convertants obtained from the sample plated raised to some exponent printed directly below the abbreviation (i.e.					
number of ADE+	For strain D4, MUT 1 represents the convertants.				
Only used for strain D4 and represents the number of TRY+ convertants in the plated sample.					
The calculated mutation or gene conversion frequency times the negative exponent written directly below. For strain D4, FREQ 1 represents the ADE+ value.					
Only used for strain D4 and represents the TRY+ conversion frequency.					
Presence of con	tamination on any plates.				
	NA1 NA2, etc. A+C A-C ACP ACT A+T LI LU KI TE 1,2, etc. All test compose whole number of identified by Example: 0025 Total number of raised to some abbreviation (Total number of from the sample printed directle of the sample of the sample printed directle of the sample of the sample printed directle of the sample o				

DATA TABLE TERMS AND ABBREVIATIONS (continued)

ABBREVIATION OR TERM	DEFINITION OR EXPLANATION
AAF .	2-Acetylaminofluorene
DMSO	Dimethylsulfoxide
DMN	Dimethylnitrosamine
EMS	Ethyl Methanesulfonate
QM	Quinacrine Mustard
NF	Nitrofluorene
SPECIES	Animal Strains
SPRDAW	Sprague Dawley Rats
ICRFLO	Flow ICR Random Bred Mice
RHÉSUS	Rhesus Monkey (<u>Macaca mulatta</u>)
MIXEDB	Dog, Mixed Breed
NEWZEA	New Zealand White Rabbit




LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM REPORT EXR34

COMPOUND FREQUENCY SUMMARY REPORT 07/08/75

SPECIES. /

. COMPOUND 977051174

TEST	ORG	TA1537 HIS FX-8	TA1535 HIS EX-8	TA1538 HIS EX-8	ADE EX-5	0000D4 TRY EX-5
NΔN		5.32	12.94	1.24	1.89	1.48
ΝΔР		1764.20	771.32	922.93	129.05	155.87
NA1		5.05	4.61	2.90	1.58	0.68
NA2		4.96	3.50	3.78	0.35	0.18



LITTON RIGHETICS MUTAGENIC ACTIVITY SYSTEM REPORT EXR34

COMPOUND FREQUENCY SUMMARY REPORT 07/08/75

SPECIES ICRELO/MOUSE COMPOUND 977051174

TEST	ORG	TA1537 HIS FX-8	TA1538 HIS EX-8	TA1535 HIS EX-8	000004 ADE EX-5	000004 TRY EX-5
ACT	A+C	20.45	6.88	3.23	2.25	1.59
ACT	A+T	35.90	6.31	7.69	3.25	1.59
' ACT	A-C	12.22	2.93	3,73	0.96	0.17
ACT	PLI	45.07	15.26	5496.88	7.59	6.16
ACT	PLU	20.50	4.48	4.79	2.42	2.60
ACT	PTE	28.79	2.33	9.15	3.81	2.06
ACT	411	9.84	6.07	3.40	1.85	2.52
ACT	L I 2	8.94	5.12	1.60	2.86	3.12
ACT.	LU1	10.21	2.35	0.84	2.68	1.79
A'C T	LU2	10.67	2.56	1.85	2.47	
ACT	TE1	9.23	1.83	7.72	1.54	1.90
ACT	TE2	7.76	3.41	3.28	3.34	1 40



LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM . REPORT EXR34

COMPOUND FREQUENCY SUMMARY REPORT 07/08/75

SPECIES SPRDAM/RAT

COMPOUND 977051174

TEST	ORG	TA1535 HIS EX-8	TA1537 HIS EX-8	TA1538 HTS EX-8	0000D4 ADE EX-5	000004 TRY EX-5
AC T	A+C	4.48	10.86	4.75	1.37	1.03
ACT	Δ+Τ	2.48	10.31	6.57	>4.61	7.21
ACT	A-C	5.52	8.87	9.05	0.49	0.49
ACT	PLI	333.15	17.19	20.33	1.90	1.27
ACT	PLU	6.11	14.09	8.76	2.38	0.59
ACT	PTE	8.60	11.40	6.77	3.14	1.73
ACT	L11	8.15	7.02	4.78	3.16	2.74
ACT	L/I2	3.25	7.59	5.60	3.35	3.35
ACT		7.35	11.19	7.76	2.41	1.85
ACT	LU2	4.48	8.43	6.95	2.90	1.88
ACT	TE1	7.46	19.35	9.11	1.90	0.95
ACT	TE2	9.93	10.11	10.18	2.48	3.51



L'ITTOM BIOMETICS MUTAGENIC ACTIVITY SYSTEM REPORT EXR34

COMPOUND FREQUENCY SUMMARY REPORT 07/08/75

SPECIES RHESUS/MONKEY COMPOUND 977051174

TEST	- ARG	TA1537 HIS EX-8	TA1535 HIS EX-8	TA1538 HIS EX-8	000004 ADE EX-5	000004 TRY EX=5
· ACT	A+C	6.36	4.50	10.43	1.82	1.82
AC T	A+T	3.92	5.62	5.80	2.59	2.73
· ACT	∇-C	5.63	7.72	2.70	2.16	1.80
ACT	PLI	10.56	1194.98	54.55	6 • 3R	3.75
ACT	PĻU	5.60	5.81	5.22	2.40	2.64
ACT	PTE	8.26	3.99	6.61	5.41	2.30
ACT	LII	5.30	5.05	3.62	3.16	3.79
ACT	1.12	5.58	4.67	7.96	1.98	2.64
ACT	LU1	4.44	6.93	3.49	1.78	2.23
AC T	rns	7.73	4.72	3.01	2.38	- 1.40
ACT	TEI	5.24	5.63	4.80	2.15	.2.62
ACT	TE2	4.55	3.05	3.46	5 • 82	1.64



VI. INTERPRETATION OF RESULTS AND CONCLUSIONS

Compound 977051174, Malt Extract, was tested for mutagenic activity in a series of in vitro microbial assays with and without metabolic activation. The following results were obtained:

- A. <u>Salmonella typhimurium</u>
- 1. Plate tests

At a concentration of 2.5%, 977051174, was not mutagenic for any of the bacterial indicator organisms in either direct or activation plate assays.

2. Nonactivation suspension tests

The results of these tests were negative.

3. Activation suspension tests

The results of these tests were negative.

- B. <u>Saccharomyces cerevisiae</u>
- 1. Nonactivation suspension tests

The results of these tests were negative.

2. Activation suspension tests

The results of these tests were negative.

C. <u>Conclusions</u>

The test compound, Malt Extract, did not exhibit genetic activity in any of the assays employed in this evaluation.

Submitted by:

David Brusick, Ph.D. Director, of Genetics

APPENDIX Tabulation of Data



EXPERIMENT	5098		22374-2104 DETECTOR TA1535	SPE	CIES	PROJECT 02468	NATE - 07/08/75
COMPOUND	TEST	ORG I:D	CONCENTRATION	POPU EP+6	MUT1 EP+0	FRFO1 FP-8	CONTAM
	NAN	4	SALINE	0487	0063	12.94	0
	NAP		EMS 0.002 %	0537	4142	771.32	0
977051174	NAI		0005-0 PCT.	0760	0035	4.61	2
977051174	NAZ		0025-1 PCT.	0799	0028	3.50	0



EXPERIMEN'			.22374-2104 DETECTOR TA1537	SPE	CIES	PROJECT 02468	DATE - 07/08/75
COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREO1 EP-8	CONTAM
	NAN	•	SALINE	0601	0032	5.32	n
	NAP		QM 1.0 UG/ML	0257	4534	1764.20	0
977051174	NAI		0005-0 PCT.	0475	0024	5.05	2
977051174	NA2		0025-1 PCT.	0484	0024	4.96	n



EXPERIMENT	CDN 5098	TRACT	22374-2104 DETECTOR TA1538	SPE	CIES	PROJECT 02468	DATE - 07/08/75
COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FRF01 EP~8	CONTAM
	NAN	,	DMSO	0563	0007	1.24	0
	NAP		NF 125 UG-ML	0567	5233	922.93	0
977051174	NAI		0005-0 PCT.	0759	0022	2.90	2
977051174	NA2		0025-1 PCT.	0873	0033	3.78	2

EXPERIMENT	5147	TRACT	22374-2104 DETECTOR 000004	SPE	CIES	PRC	DJECT 024	68	DATE - 07/08/75
COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+4	MUT1 EP+1	MUT2 EP+1	FREQ1	FRF02 FP-5	•
	NAN		SALINE	0741	0014	0011	1.89	1.48	0
	NAP		FMS 1.0 %	0179	0231	0279	129.05	155.87	0
977051174	NAI		0005-0 PCT.	0442	0007	0003	1.58	0.68	0
977051174	NAZ		0025-1 PCT.	0564	0002	0001	. 0.35	0.18	O



	CONTRACT		22374-2104		PROJECT 02468						
EXPERIMENT	T 5094	01	DETECTOR TA1535	SPE	CIES I	CRELD/MOUSE	DATE - 07/08/75				
		ORG		POPU	MUTI	FRE01	•				
COMPOUND	TEST	10	CONCENTRATION	EP+6	EP+O.	FP-8	CONTAM				
	A+C		DMN 50 UM/ML	0650	0021	3.23	. 0				
	Δ+Τ		***NO MATCH***	0156	0012	7.69	0				
	V-C		SALINE	0670	0025	3.73	1				
	ACP	LI	DMN 50 UM/ML	0096	5277	5496.88	n				
	ACP	LU	DMN 50 UM/ML	0313	0015	4.79	0				
	ACP	TE	DMN 50 UM/ML	0153	0014	9.15	0				
977051174	ACT	LII	0005-0 PCT.	0500	0017	3.40	0				
977051174	ACT	ris	0025-1 PCT.	0437	0007	1.60	2				
977051174	ACT	LU1	0005-0 PCT.	0596	0005	0.84	?				
977051174	ACT	LU2	0025-1 PCT.	0486	0009	1.85	?				
977051174	ACT	TF1	0005-0 PCT.	0544	0042	7.72	0				
977051174	ACT	TE2	0025-1 PCT.	0396	0013	3.28	0				

EXPERIMEN.	CO T 517	NTRACT 602	72374-2104 DETECTOR TA1537	7 SPI	ECIES IC	PROJECT 02468 CRELO/MOUSE	DATE - 07/08/75
COMPOUND	TEST	NRG ID	CONCENTRATION	POPU EP+6	MUT1 EP+O	FRFO1 .	CONTAM
•	Δ+C		AAF 800 UG/ML	0308	0063	20.45	0
	A+T		***NO MATCH***	0078	0028	35.90	1
	A-C		DMSO	0483	0059	12.22	0
	ACP	LI	AAF 800 UG/ML	0071	0032	45.07	
	ACP	LU	AAF 800 UG/ML	0161	0033	20.50	0
	AÇP	TE	AAF 800 UG/ML	0198	0057	28.79	0
977051174	ACT	LII	0005-0 PCT.	0823	0081	9.84	0
977051174	ACT	LI2	0025-1 PCT.	0850	0076	8.94	0
977051174	ACT	LU1	0005-0 PCT.	0754	0077	10.21	0
977051174	ACT	LU2	0025-1 PCT.	0450	0048	10.67	2
977051174	ACT	TF1	0005-0 PCT.	0607	0056	9.23	0
977051174	ACT	TE2	0025-1 PCT.	0490	0038	7.76	1



EXPERIMENT 509701 D			22374-2104 DETECTOR TA1538	SPE	CIES	PROJECT 02468 ICRELO/MOUSE	DATE - 07/08/75
COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT] EP+0	* ** ** ***	CONTAM
	A+C		AAF 800 UG/ML	0858	0059	6.88	n
	Δ+T		***NO MATCH***	0666	0042	6.31	0
	A-C		DMSO	0819	0024	2.93	0
	ACP	LI	AAF 800 UG/ML	0675	0103	15.26	0
:	ACP	LU	AAF 800 UG/ML	1026	0046	4.48	2
,	ACP	TE	A'AF 800 UG/ML	0945	0022	2.33	0
977051174	ACT	LII	0005-0 PCT.	0478	0029	6.07	. Ó
977051174	ACT	L I 2	0025-1 PCT.	0664	0.034	5.12	0
977051174	ACT	LU1	0005-0 PCT.	0638	0015	2.35	. 2
977051174	ACT	LU2	0025-1 PCT.	0780	0020	2.56	?
977051174	ACT	TE1	0005-0 PCT.	0711	0013	1.83	0
977051174	ACT	TE2	0025-1 PCT.	0734	0025	3.41	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM COMPOUND SUMMARY BACKUP DETAIL

	CON	TRACT	22374-2104		•	PRO.	JECT 0240	58	
EXPERIMENT	5126	01	DETECTOR 000004	SPF	CIES I	CRELOZA	MOUSE		DATE - 07/08/75
COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+4	MUT1 EP+1	MUT2 FP+1	FREO1 EP-5	EREO2	CUNTAM
	Δ+C		DMN 90 UM/ML	0755	0017	0012	2.25	1.59	n
	Δ + T		***NO MATCH***	1260	0041	0020	3.25	1.59	6
	A-C		SALINE	1145	0011	0002	0.96	0.17	Ò
	ACP	LI	DMN 90 UM/ML	0909	0069	0056	7.59	6.16	6
	ACP	LU	DMN 90 UM/ML	1117	0027	0029	2.42	2.60	. 0
	ACP	TE	DMN 90 UM/MI_	0970	0037	0020	3.81	2.06	6
977051174	ACT	LI1	0005-0 PCT.	0755	0014	.0019	1.85	2.52	4
977051174	ACT	LI2	0025-1 PCT.	0770	0022	0024	2.86	3.12	?
977051174	ACT	LU1	0005-0 PCT.	0895	0024	0016	2.68	1.79	1
977051174	ACT	LU2	0025-1 PCT.	0849	0021	0018	2.47	2.12	1
977051174	ACT	TE1	0005-0 PCT.	0844	0013	0016	1.54	1.90	2
977051174	ACT	TF2	0025-1 PCT.	0689	0023	0011	3.34	1.60	6



CONTRACT EXPERIMENT 510801			22374-2104 DETECTOR TA1535	S SPF	CIES SPE	PROJECT 02468 RDAW/RAT	DATE - 07/08/75	
COMPOUND	ት ሮር ተ	ORG	68465455455	POPU	MUT1	FRE01	•	
COMPTONIO	TEST	ΙD	CONCENTRATION	EP+6	EP+0	FP-8	CONTAM	
	A+C	•	DMN 50 HM/ML	0692	0031	4.48	Ó	
	A+T		***NO MATCH***	0483	0012	2.48	3	
	A-C		SALINE	0725	0040	5.52	n	
	ACP	LI	DMN 50 UM/ML	0368	1226	333.15	1	
	ACP	LU.	DMN 50 UM/ML	0311	0019	6.11	0	-
	ACP	ŢĘ	DMN 50 UM/ML	0349	0030	8.60	0	
977051174	ACT	LI1	0005-0 PCT.	0552	0045	8.15	3	
977051174	ACT	LI2	0025-1 PCT.	0553	0018	3.25	2	
977051174	ACT	LU1	0005-0 PCT.	0517	0038	7.35		
977051174	ACT	LU2	0025-1 PCT.	0536	0024	4.48	0	
977051174	ACT	TE1	0005-0 PCT.	0469	00.35	7.46	0	
977051174	ACT	TE2	0025-1 PCT.	0614	0061	9.93	2	

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM COMPOUND SUMMARY BACKUP DETAIL

EXPERIMEN	COM T 5115	NTRACT 501	22374-2104 DETECTOR TA1537	SPE	CIES SPRE	PROJECT 02468 DAW/RAT	DATE - 07/08/75
COMPOUND	TEST	NRG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREO1	CONTAM
•	A+C	•	AAF 800 UG/ML	0663	0072	10.86	0
	A+T		***NO MATCH***	0446	0046	10.31	n
	A-C		DMSO	0688	0061	8.87	. 0 .
	ACP	LI	AAF 800 UG/ML	0512	0088	17.19	2
	ACP	LU	AAF 800 UG/ML	0589	0083.	14.09	0
	ACP	TE	AAF 800 UG/ML	0544	0062	11.40	0
977051174	ACT	LII	0005-0 PCT.	0712	0050	7.02	2
977051174	ACT	LI2	0025-1 PCT.	0632	0048	7.59	2
977051174	AC T	LU1	0005=0 PCT.	0590	0066	11.19	
977051174	ACT	LU2	0025-1 PCT.	0617	0052	8.43	2
977051174	ACT	TE1	0005-0 PCT.	0465	0090	19.35	0
977051174	ACT	TE2	0025-1 PCT.	0613	0062	10.11	0



EXPERIMENT	COI 511	NTRACT BO1	22374-2104 DETECTOR TA1538	8 SP	ECIFS	PROJECT 02468 SPRDAW/RAT	DATE - 07/08/75
COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 FP+0	1 (71, 101)	CONTAM
	A+C		AAF 800 UG/ML	0926	0044	4.75	0
	A+T		***NU WYICH***	0792	0052	6.57	0
	A-C		DMSO	0707	0064	9.05	0
	ACP	LI	AAF 800 UG/ML	0718	0146	20.33	2
	ACP	LU	AAF 800 HG/ML	0833	0073	8.76	<u>, </u>
•	ACP	TE	AAF 800 UG/ML	088,6	0060	6.77	?
977051174	ACT	LII	0005-0 PCT.	0648	0031	4.78	2 -
977051174	ACT	LI2	0025-1 PCT.	0625	0035	5.60	0
977051174		LUI	0005-0 PCT.	0670	0052	7.76	· ····· · · · · · · · · · · · · · · ·
977051174	ACT	LU2	0025-1 PCT.	0834	0058	6.95	0
	ACT	TE1	0005-0 PCT.	0571	0052	9.11	0
977051174	ACT	TE2	0025-1 PCT.	0717	0073	10.18	0



EXPERIMENT	COM 5150	NTRACT DO1	22374-2104 DETECTOR 000004	SPE	ECIES S	PRO. PRDAW/F	JECT 024 RAT	68	DATE - 07/08/75
COMPUUND	TEST	ORG ID	CONCENTRATION	POPU EP+4	MUT1 EP+1	MUT2 EP+1	EREO1	FRF02 FP-5	
	A-C		SALINE	0610	0003	0003	0.49	0.49	0
977051174	ACT	LII	0005-0 PCT.	0475	0015	0013	3.16	2.74	n
977051174	ACT	LI2	0025-1 PCT.	0568	0019	0019	3.35	3.35	0
977051174	ACT	ĽU1	0005-0 PCT.	0540	0013	0010	2.41	1.85	0
977051174	ACT	LU2	0025-1 PCT.	0586	0017	0011	2.90	1.88	0
977051174	ACT	TF1	0005-0 PCT.	0525	0010	0005	1.90	0.95	0
977051174	ACT	TE2	0025-1 PCT.	0484	0012	0017	2.48	3.51	0
	·A+C		DMN 90 UM/ML	0584	8000	0006	1.37	1.03	2
	A+T			0499	0023	0036	4161	7.21	6
	ACP	Lī	DMN 90 UM/ML	0473	0009	0006	1.90	1.27	<u> ,</u>
	ACP	LU	DMN 90 UM/ML	0505	0012	0003	2.38	0.59	2
	ACP	TE	DMN 90 UM/ML	0 6 37	0020	0011	3.14	1.73	0

	CON	ITRACT	22374-2104	PROJECT 02468							
EXPERIMENT	5099	01	DETECTOR TA1535	SPE	CIES R	HESUS/MONKEY	DATE - 07/08/75				
		ORG		POPU	MUT1	FREOL	•				
COMPOUND	TEST	ID	CONCENTRATION	EP+6	FP+0	EP-8	CONTAM				
	A+C		DMN 50 UM/ML	0756	0034	4.50	0				
• •	Δ÷Τ		***NO MATCH***	0534	0030	5.62	0				
	- A -C		SALINE	0479	0037	7.72	1				
	ACP	LI	DMN 50 UM/ML	0458	5473	1194.98	o 1				
	ACP	LU	DMN 50 UM/ML	0551	0032	5.81	0				
	ACP	TE	DMN 50 UM/ML	0426	0017	3.99	2				
977051174	ACT	LII	0005-0 PCT.	0673	0034	5.05	0				
977051174	ACT	LI2	0025-1 PCT.	0600	0028	4.67	0				
977051174	ACT	LHI	0005-0 PCT.	0635	0044	6.93	··· 0 ·				
977051174	ACT	LU2	0025-1 PCT.	0593	0028	4.72	2				
977051174	ACT	TE1	0005-0 PCT.	0497	0028	5.63	2				
977051174	ACT	TE2	0025-1 PCT.	0721	0022	3.05	2				



EXPERIMENT			22374-2104 DETECTOR TA1537	SPE	CIFS RHI	PROJECT 02468 FSUS/MONKEY	DATE - 07/08/75
•		ORG		PNPU	MUT1	FREO1	•
CUMPOUND	TEST	ID	CONCENTRATION	EP+6	EP+0	EP-8	CONTAM
	A+C		AAF 800 UG/ML	0692	0044	6.36	0
	A+T		***NO MATCH***	0638	0025	3.92	0
	A-C		DMSO	0533	0030	5.63	0
	ACP	LI	AAF 800 UG/ML	0606	0064	10.56	0
	ACP	LU	AAF 800 HG/ML	0643	0036	5.60	0
	ACP	TE	AAF 800 UG/ML	0545	0045	8.26	0
977051174	ACT	LII	0005-0 PCT.	0491	0026	5.30	2
977051174	ACT	LI2	0025-1 PCT.	0538	0030	5.58	0
977051174	ACT	LU1	0005-0 PCT.	0405	-0018	4.44	n
977051174	ACT	LU2	0025-1 PCT.	0440	0034	7.73	2
977051174	ACT	TE1	0005-0 PCT.	0477	0025	5.24	2
977051174	ACT	TE2	0025-1 PCT.	0505	0023	4.55	0

EXPERIMENT			22374-2104 DETECTOR TA1538	SPE	CIES RH	PROJECT 02468 ESUS/MONKEY	DATE - 07/08/75
CUMPUUND	TECT	ORG	0.004.0.54.754.4.754	POPU	MUT1	FREQI	•
COMPOUNT	TEST	ID .	CONCENTRATION	EP+6	EP+0	FP-A	CONTAM
	A+C		AAF 800 UG/ML	0748	0078	10.43	. 0
	A+T		***NU WATCH***	0742	0043	5.80	2
	A-C		DMSO	0742	0020	2.70	?
	ACP	LI	AAF 800 UG/ML	0638	0348	54.55	n
,	ACP	LU	AAF 800 UG/ML	0901	0047	5.22	0
	ACP	TE	AAF 800 UG/ML	0681	0045	6.61	. 0
977051174	ACT	LI1	0005-0 PCT.	0719	0026	3.62	0
977051174	ACT	LI2	0025-1 PCT.	0678	0054	7.96	0
977051174	ACT	LU1	0005-0 PCT.	0717	0025	3.49	2
977051174	ACT	LU2	0025-1 PCT.	0863	0026.	3.01	2
977051174	ACT	TE1	0005-0 PCT.	0875	0042	4.80	?
977051174	ACT	TE2	0025-1 PCT.	0926	0032	3.46	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM COMPOUND SUMMARY BACKUP DETAIL

EXPERIMENT				22374-2104 DETECTOR 000004	SPF	ECIES F	PRO. RHESUS/A	DATE 07/00/75			
	COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+4	MIT1	MUT2 EP+1	FREO1 EP-5	FRE02 EP-5	DATE - 07/08/75	
		A+C		DMN 90 UM/ML	0658	0012	0012	1.82	1.82	1	
	,	A+T		***NO WOTCH***	0695	0018	0019	2.59	2.73	1	
		A-C		SALINE	0555	0012	0010	2.16	1.80	1 1 7	
		ACP	LI	DMN 90 UM/ML	0799	0051	0030	6.38	3.75	• 0	
		ACP	LU	DMN 90 UM/ML	0832	0020	0022	2.40	2.64	1	
		ACP	TE	DMN 90 UM/ML	0739	0040	0017	5.41	2.30	4	
	977051174	ACT	LII	0005-0 PCT.	0475	0015	0018	3.16	3.79	1 ·	
	977051174	ACT	Lİ2	0025-1 PCT.	0455	0009	0012	1.98	2.64	0	
	977051174	ACT	LUI	0005-0 PCT.	0674	0012	0015	1.78	2.23		`
	977051174	ACT	LII2	0025-1 PCT.	0714	0017	0010	2.38	1.40	0	
	977051174	ACT	TE1	0005-0 PCT.	0650	0014	0017	2.15	2.62	0	
	977051174	ACT	TF2	0025-1 PCT.	0550	0032	0009	5.82	1.64	0	
				•						4	